Deans' stroke musings: Maintaining Momentum in Parkinson’s Research

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, February 18, 2021

Maintaining Momentum in Parkinson’s Research

If ANYTHING EXISTS LIKE THIS IN STROKE, I DON'T SEE IT. And until we get survivors in charge, NOTHING WILL OCCUR.

Maintaining Momentum in Parkinson’s Research

Last year, backed by dedicated donors like you, The Michael J. Fox Foundation (MJFF) awarded $75 million in 231 grants to projects designed to translate promising research into real solutions for people living with Parkinson’s.

In 2021, we are determined to keep the momentum going by funding even more research to advance the next life-changing breakthrough. Please consider renewing your investment in MJFF’s 2021 vision by donating today.

Patients’ greatest need remains a therapy to slow or stop progression of the disease. To meet that need, we are building a diversified portfolio of targets and treatments that gives us more shots on goal toward more wins for the Parkinson’s community. Here’s a snapshot of what’s in the pipeline:

Today, more than 20 approaches focused on three key genetic targets — alpha-synuclein, LRRK2 and GBA — have entered human trials, with many more in pre-clinical development.

Five treatments are currently in human trials for inflammation, which impacts neurodegenerative diseases and has ties to genetic factors and the environment.

Studies of approved treatments with the potential to be repurposed for Parkinson’s continue, including one MJFF-funded project investigating a drug for enlarged prostate after it was linked to lower PD risk.

Every project serves a unique purpose as we work quickly to gather more insight into the disease and illuminate pathways to stop, slow and ultimately end Parkinson’s for good. Your donation ensures no stone is left unturned.